ActRIIB ectodomain variants treating metabolic disorders and fibrosis
Summary
USPTO published patent application US20260092096A1 for Activin receptor type IIB (ActRIIB) ectodomain variants fused to Fc domain for treating metabolic disorders, diabetes, obesity, fibrosis, and muscle atrophy. The application (No. 19206991) was filed May 13, 2025, by inventors Maureen D. O'Connor-McCourt et al.
What changed
USPTO published patent application US20260092096A1 disclosing polypeptides comprising ActRIIB ectodomain variants, optionally fused to an Fc domain moiety. The claimed inventions are directed to treating diseases associated with TGFβ superfamily ligand signaling, including metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and anemia. CPC classifications include C07K 14/71 and A61P 3/04.
This patent application publication does not impose compliance obligations on third parties. Pharmaceutical companies, biotechnology firms, and researchers developing ActRIIB-related therapeutics should review the claims to assess potential freedom-to-operate implications or licensing opportunities. No response or action is required from the public.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ACTIVIN RECEPTOR TYPE IIB VARIANTS AND USES THEREOF
Application US20260092096A1 Kind: A1 Apr 02, 2026
Inventors
Maureen D. O'CONNOR-MCCOURT, Vannakambadi K. Ganesh, Gilles Tremblay, Gauthier Schang
Abstract
There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and/or low red blood cell levels (such as anemia).
CPC Classifications
C07K 14/71 A61P 3/04 A61K 38/00 C07K 2319/30
Filing Date
2025-05-13
Application No.
19206991
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.